No Data
No Data
RBC Capital Maintains Pactiv Evergreen(PTVE.US) With Hold Rating, Maintains Target Price $18
RBC Capital Reaffirms Their Hold Rating on Pactiv Evergreen (PTVE)
Pactiv Evergreen Reports Expiry of Waiting Period for Acquisition by Novolex
Pactiv Evergreen Announces Expiration Of HSR Act Waiting Period For Acquisition By Novolex At $18/Share, Expected To Close In Q2 2025; Will Become Private, Nasdaq Delisting Expected Upon Transaction Completion
Express News | Pactiv Evergreen Inc - Upon the Completion of Transaction, to Become Privately Held, Delist From Nasdaq
Express News | Pactiv Evergreen Inc - Evergreen-Novolex Deal Expected to Close in Q2 2025